FDA approves first treatment that delays diabetes

0

The Food and Drug Administration (FDA) on Thursday approved the first drug that delays the onset of a stage of Type 1 diabetes.

“Today’s approval of a first-in-class therapy adds an important new treatment option for certain at-risk patients,” said John Sharretts, the director of the Division of Diabetes, Lipid Disorders and Obesity in the FDA’s Center for Drug Evaluation and Research, in an announcement.

“The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease.”

Injections of the diabetes drug Tzield are now approved for use to delay the onset of stage 3 Type 1 diabetes among adults and children 8 years and older who have stage 2 of the disease.

Type 1 diabetes occurs when immune cells are triggered to attack and destroy cells producing insulin. The disease progresses into stage 3 when a person has lost a significant proportion of their insulin-producing cells.

Tzield binds to immune system cells and is thought to possibly deactivate the dysfunctional cells attacking insulin-producing cells, thereby moderating the body’s immune response.

Patients who suffer from Type 1 diabetes can be treated with Tzield by receiving injections of the drug daily for 14 days.

Side effects of Tzield may include decreased white blood cell levels, rash and headache, according to the FDA.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health & Fitness News Click Here 

Read original article here

Denial of responsibility! Rapidtelecast.com is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment